Top-News
Chemikalien USA

Cytokinetics News

Aktie
WKN:  A1W1KK ISIN:  US23282W6057 US-Symbol:  CYTK
45,80 €
+0,40 €
+0,88%
31.05.24 11:09:38
Handeln Depot/Watchlist
Aktienanzahl *
98,05 Mio.
Marktkapitalisierung *
4,38 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 27.12.2023

Unternehmensmeldungen

13.05.15 - GlobeNewswire
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics to Hold Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced ...
08.04.15 - GlobeNewswire
Cytokinetics to Present at the 14th Annual Needham Healthcare Conference
Cytokinetics to Present at the 14th Annual Needham Healthcare Conference South San Francisco, CA, April 8, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today ...
25.03.15 - GlobeNewswire
Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis
Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis Data from Evidence of Effect Trial Provide Support for Novel ...
13.03.15 - GlobeNewswire
Cytokinetics Announces Completion of Enrollment in COSMIC-HF
Cytokinetics Announces Completion of Enrollment in COSMIC-HF Results Expected Later This Year to Inform Potential Progression of Omecamtiv Mecarbil to Phase III SOUTH ...
27.02.15 - GlobeNewswire
Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases
Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases SOUTH SAN FRANCISCO, CA, February 27, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK) ...
26.02.15 - GlobeNewswire
Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure
Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure Manuscript Supports Rationale for ...
24.02.15 - GlobeNewswire
Cytokinetics to Present at Healthcare Conferences in March
Cytokinetics to Present at Healthcare Conferences in March South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today that Robert ...
23.12.14 - GlobeNewswire
Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications
Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications Cytokinetics ...
05.12.14 - GlobeNewswire
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND South San Francisco, CA, ...
01.12.14 - GlobeNewswire
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND South San Francisco, CA, December 1, 2014 - Cytokinetics, ...
26.11.14 - GlobeNewswire
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference South San Francisco, CA, November 26, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) ...
10.11.14 - GlobeNewswire
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute SOUTH SAN FRANCISCO, CA, November 10, ...
27.10.14 - GlobeNewswire
Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil
Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil Over 275 Patients Enrolled in COSMIC-HF; Data Monitoring Committee Recommends Continuation ...
20.10.14 - GlobeNewswire
Cytokinetics Provides Development Program Update for Tirasemtiv
Cytokinetics Provides Development Program Update for Tirasemtiv Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-​ALS Support Progression to Phase III ...
16.10.14 - GlobeNewswire
Cytokinetics to Announce Third Quarter Results on October 30, 2014
Cytokinetics to Announce Third Quarter Results on October 30, 2014 South San Francisco, CA., October 16, 2014, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that ...
13.10.14 - GlobeNewswire
Cytokinetics Announces Development Program Update for CK-2127107
Cytokinetics Announces Development Program Update for CK-2127107 Company Completes Program of Five Phase I Clinical Trials Pursuant to Agreed Development Plan with ...
07.08.14 - GlobeNewswire
Cytokinetics to Present at the 34th Annual Canaccord Global Growth Conference
Cytokinetics to Present at the 34th Annual Canaccord Global Growth Conference South San Francisco, CA, August 7, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK ) announced ...
16.07.14 - GlobeNewswire
Cytokinetics to Announce Second Quarter Results on July 30, 2014
Cytokinetics to Announce Second Quarter Results on July 30, 2014 South San Francisco, CA., July 16, 2014, - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is ...
10.07.14 - GlobeNewswire
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup Analyses of BENEFIT-ALS
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-​Specificed Subgroup Analyses of BENEFIT-​ALS Effects of Tirasemtiv on Slow Vital Capacity During 12 ...
03.07.14 - GlobeNewswire
Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International Congress on Neuromuscular Diseases
Cytokinetics Announces Additional Data from BENEFIT-​ALS to be Presented at the 13th International Congress on Neuromuscular Diseases South San Francisco, CA, July 3, 2014 -...

Newssuche

Videos

29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »